跳到主要內容區塊/Jump To Main Area :::
:::
Pharmaceutics
Research & Technology > Pharmaceutics

DCB's Institute of Pharmaceutics is dedicated to the development of small molecule drugs and therapeutic technologies that are improvements and optimizations of existing drug molecules. The Institute of Pharmaceutics comprises two core groups: Pharmaceutics and Botanical Drugs.

With over 70 researchers specializing in medicinal chemistry, the Pharmaceutics Group focuses on target discovery and validation; hit finding; lead compounds identifica- tion; synthesis and optimization; pharmacokinetic study design and interpretation; drug stability profiles; and off-target toxicity analysis. Importantly, we also possess proprietary ADC technolo- gies that combine site-specific conjugation with proprietary linkers and payloads optimized for safety, efficacy and biophysical properties.

Our Botanical Drugs Groups pecializes in natural-product formulation, plant authentication, and CMC (chemistry, manufacturing, and control) for botanical drugs and natural products. The Botanical Drugs Group can provide integrative services from material development and DNA identification to consultation for Investigational New Drug (IND) submissions as well as CMC.

 

DCB's Institute of Pharmaceutics works with target validation, medical chemistry, Drug analysis and formulation, in Vitro biology and botanical drug development.

:::